Updated on 7 September 2026
WPD is seeking strategic pharmaceutical and biotechnology partners for co-development, licensing and commercialization of WPD401
About
WPD is seeking strategic pharmaceutical and biotechnology partners for co-development, licensing and commercialization of WPD401 and its broader targeted-oncology platform. The primary opportunity is WPD401 in recurrent glioblastoma, with potential expansion into newly diagnosed GBM, brain metastases and other receptor-positive tumors. WPD is particularly interested in partners with capabilities in ADC/PDC development, CNS oncology, innovative blood–brain barrier delivery, clinical development and global commercialization.